A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

NCT ID: NCT03962062

Last Updated: 2025-09-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-29
• Study Completion Date: 2022-09-28

Brief Summary

The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over. The secondary purpose is to evaluate the safety and pharmacokinetics of a single dose of moxidectin in children and adolescents aged 4 to 17 years.

Conditions

Onchocerciasis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1: 12-17 years

Moxidectin 8mg per oral, single dose

Group Type: EXPERIMENTAL

Moxidectin

Intervention Type: DRUG

2 mg tablets

Cohort 2: 8-11 years

Moxidectin 8mg (or lower dose) per oral, single dose

Group Type: EXPERIMENTAL

Moxidectin

Intervention Type: DRUG

2 mg tablets

Cohort 3: 4-7 years

Moxidectin single dose, determined by population pharmacokinetic modelling including data from Cohorts 1 and 2

Group Type: EXPERIMENTAL

Moxidectin

Intervention Type: DRUG

2 mg tablets

Interventions

Moxidectin

2 mg tablets

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Aged 4 to 17 years, inclusive:

1. Cohort I: 12 to 17 years;

2. Cohort II: 8 to 11 years;

3. Cohort III: 4 to 7 years;

2. Live in a region designated by the World Health Organization (WHO) as endemic for O. volvulus infection (World Health Organization, 2019). Specifically, participants will be recruited from the Kpassa sub-district of the Nkwanta North district.The specific communities will include Wii, Jagri-Do, and Azua where mass drug administration with ivermectin for onchocerciasis commenced in October 2017;

3. Willing and able to remain at the study clinic from Screening up to Day 7;

4. Provision of parental or guardian written informed consent and assent / lack of expression of 'deliberate objection' (as appropriate for age);

5. Females of childbearing potential must commit to using a reliable method of contraception as per local family planning guidelines from Baseline (pre-treatment on Day 0) until approximately 6 months after treatment with study drug.

Exclusion Criteria

1. History of serious medical or psychiatric condition which, in the opinion of the investigator, would put the subject at increased risk by participating in the study or jeopardize study outcomes;

2. Known or suspected concurrent clinically significant renal, cardiac, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease), immunological disorders or malignancy, congenital heart disease, chronic lung disease;

3. Has received an investigational product within 28 days or 5 half-lives of Baseline, whichever is longer;

4. Has received ivermectin or any other anti-helminthic treatments within 28 days of Baseline;

5. Has received a vaccination within 7 days of Baseline;

6. Known or suspected hypersensitivity to macrocyclic lactones or excipients used in the formulation of moxidectin;

7. Poor venous access;

8. Unable to swallow tablets (flat oval, 8.0 millimeters (mm) x 4.5 mm x 3.0 mm);

9. Weight:

1. Cohort I (12 to 17 years): < 30 kg;

2. Cohort II (8 to 11 years): < 18 kg;

3. Cohort III (4 to 7 years): < 12 kg;

10. Clinically relevant laboratory abnormalities at Screening, including:

1. Hemoglobin < 9.5 grams per deciliter (g/dL);

2. Neutrophil (granulocyte) count < 1.5 x 109/L;

3. Platelet count < 110 x 109/L;

4. Alanine aminotransferase (ALT) > 1.5 times the upper limit of normal range (ULN);

5. Total bilirubin > 1.5 times ULN;

11. Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) positive;

12. Known or suspected malaria or other ongoing viral, bacterial, or plasmodium infection at Screening and/or Baseline;

13. Loa loa co-infection;

14. Unwilling, unlikely or unable to comply with all protocol specified assessments;

15. For females of child bearing potential, pregnant or breastfeeding, or planning to become pregnant;

16. Previous enrolment in this study;

17. Is a sibling of another child already enrolled in this study.

• Minimum Eligible Age: 4 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medicines Development for Global Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nicholas O Opoku, MD

Role: PRINCIPAL_INVESTIGATOR

University of Health and Allied Sciences School of Public Health, Hohoe, Ghana

Locations

University of Health and Allied Services School of Public Health

Hohoe, Volta Region, Ghana

Countries

Ghana

References

Opoku NO, Doe F, Agbogah ME, Laryea R, Gordor SK, Donkor BS, Anyomitse E, Kugali D, van Zutphen-van Geffen M, Navarro DJ, Rayner CR, Patel K, Kuesel AC, Lowe M, Kinrade S. Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study. Parasit Vectors. 2025 Jul 24;18(1):295. doi: 10.1186/s13071-025-06891-z.

Reference Type: RESULT

PMID: 40707999 (View on PubMed)

Provided Documents

Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form

View Document

Related Links

https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-025-06891-z

Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study.

Other Identifiers

MDGH-MOX-1006

Identifier Type: -

Identifier Source: org_study_id